Pre-treatment of the beta3-adrenergic receptor agonist BRL37344 reduces in vivo myocardial ischemia/reperfusion injury by improving AMPK and SIRT1 activity and by suppressing mTOR and p70S6K signaling pathwaysDilan AŞKIN ÖZEK, Engin Şahna|Brazilian Journal of Pharmaceutical Sciences|2023Cited by 0